Zymeworks Inc. (NYSE:ZYME - Free Report) - Equities research analysts at Leerink Partnrs reduced their Q4 2024 earnings per share (EPS) estimates for Zymeworks in a report issued on Thursday, November 7th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn $0.70 per share for the quarter, down from their previous forecast of $0.86. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Zymeworks' current full-year earnings is ($1.05) per share.
Zymeworks (NYSE:ZYME - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.01. The firm had revenue of $16.00 million during the quarter, compared to the consensus estimate of $17.90 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The company's revenue was down 3.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.41) EPS.
A number of other analysts have also recently weighed in on ZYME. Citigroup upped their price target on shares of Zymeworks from $16.00 to $18.00 and gave the stock a "buy" rating in a research report on Monday. HC Wainwright reaffirmed a "neutral" rating and issued a $12.00 target price on shares of Zymeworks in a research report on Friday, November 1st. Leerink Partners upgraded Zymeworks from a "market perform" rating to an "outperform" rating and raised their target price for the company from $10.00 to $25.00 in a report on Thursday. Stifel Nicolaus upped their price target on Zymeworks from $21.00 to $28.00 and gave the stock a "buy" rating in a report on Monday, October 28th. Finally, Wells Fargo & Company downgraded shares of Zymeworks from an "overweight" rating to an "equal weight" rating and set a $12.00 price objective for the company. in a research report on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $19.00.
Get Our Latest Stock Report on ZYME
Zymeworks stock opened at $16.77 on Friday. The firm has a fifty day moving average of $12.90 and a 200-day moving average of $10.64. Zymeworks has a 52-week low of $6.83 and a 52-week high of $17.26. The firm has a market capitalization of $1.16 billion, a P/E ratio of -11.18 and a beta of 1.16.
Hedge funds have recently bought and sold shares of the business. DekaBank Deutsche Girozentrale acquired a new position in shares of Zymeworks in the 3rd quarter valued at approximately $47,000. Quest Partners LLC lifted its position in shares of Zymeworks by 8,049.6% during the second quarter. Quest Partners LLC now owns 9,209 shares of the company's stock worth $78,000 after purchasing an additional 9,096 shares during the last quarter. nVerses Capital LLC acquired a new position in Zymeworks in the third quarter worth about $79,000. MQS Management LLC bought a new stake in Zymeworks in the second quarter valued at about $92,000. Finally, Arizona State Retirement System raised its stake in Zymeworks by 11.1% during the second quarter. Arizona State Retirement System now owns 12,841 shares of the company's stock valued at $109,000 after buying an additional 1,285 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company's stock.
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Zymeworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.
While Zymeworks currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.